Login
$PSHG
$1.64 -$0.01 (0.61%) Close

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q4 FY2025
As of Dec 31, 2025
Q4 FY2024
As of Dec 31, 2024
Q4 FY2023
As of Dec 31, 2023
Q4 FY2022
As of Dec 31, 2022
Q4 FY2021
As of Dec 31, 2021
Q4 FY2020
As of Dec 31, 2020
Q4 FY2019
As of Dec 31, 2019
Q4 FY2018
As of Dec 31, 2018
Q4 FY2017
As of Dec 31, 2017
Q4 FY2016
As of Dec 31, 2016
Q4 FY2015
As of Dec 31, 2015
Q4 FY2014
As of Dec 31, 2014
Q4 FY2013
As of Dec 31, 2013
Q4 FY2012
As of Dec 31, 2012
ASSETS
CURRENT ASSETS:
Cash and cash equivalents
Accounts receivable, net (Note 3)
Deferred voyage expenses (Note 2 (n))
Inventories
EU allowances (Note 3)
Prepaid expenses and other assets
Restricted cash (Note 6)
Current assets from discontinued operations (Note 2 (y))
Total current assets
FIXED ASSETS:
Advances for vessels under construction and other vessels' costs (Note 5)
Vessels, net (Note 6)
Property and equipment, net
Total fixed assets
NON-CURRENT ASSETS:
Restricted cash, non-current (Note 7)
Right of use asset under operating leases
Compensating cash balance
Deferred charges, net
Other non-current assets
Prepaid charter revenue
Total non-current assets
Total assets
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Current portion of long-term debt, net of unamortized deferred financing costs (Note 7)
Accounts payable, trade and other
Due to related parties (Note 4)
Accrued liabilities (Note 7)
Deferred revenue (Note 3)
Lease liabilities, current
Current liabilities from discontinued operations (Note 2 (y))
EU allowances liability
EU allowances liability (Note 3)
Total current liabilities
LONG-TERM LIABILITIES:
Long-term debt, net of unamortized deferred financing costs (Note 7)
Bonds, net of unamortized discounts and deferred financing costs (Note 7)
Other liabilities, non-current
Long-term lease liabilities
Commitments and contingencies (Note 8)
Fair value of warrants' liability (Note 9)
Total long-term liabilities
STOCKHOLDERS' EQUITY:
Preferred stock, $0.01 par value; 25,000,000 shares authorized, 50,726 and 50,726 Series B, and 1,423,912 and 1,423,912 Series C issued and outstanding as at December 31, 2025 and 2024, respectively (Note 9)
Common stock, $0.01 par value; 500,000,000 shares authorized; 12,432,158 and 12,432,158 issued and outstanding as at December 31, 2025 and 2024, respectively (Note 9)
Additional paid-in capital (Note 9)
Other comprehensive income
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders' equity

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support